Insights into the future of first-line advanced hepatocellular carcinoma treatment

被引：0
|
作者：
Wong, Jeffrey Sum Lung [1 ]
Wong, Carmen Chak-Lui [2 ]
Sun, Frances Sze Kei [1 ]
Yau, Thomas [1 ,3 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China
[3] Univ Hong Kong, Ctr Canc Med, Hong Kong, Peoples R China
来源：
LANCET ONCOLOGY | 2025年 / 26卷 / 02期
关键词：
ATEZOLIZUMAB; BEVACIZUMAB;
D O I：
10.1016/S1470-2045(24)00728-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：152 / 153
页数：2
相关论文
共 50 条
  • [31] Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Lin, Yuxuan
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [32] The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
    Lee, Shou-Wu
    Yang, Sheng-Shun
    Lien, Han-Chung
    Peng, Yen-Chun
    Tung, Chun-Fang
    Lee, Teng-Yu
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [33] Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 96 - 96
  • [34] Bevacizumab - In first-line treatment of advanced and/or metastatic renal cell carcinoma
    Frampton, James E.
    Keating, Gillian M.
    BIODRUGS, 2008, 22 (02) : 113 - 120
  • [35] Doxorubicin, Etoposide and Cisplatin as First-Line Treatment in Advanced Adrenocortical Carcinoma
    Jimenez Fonseca, F.
    Vieitez, J. M.
    Crespo, G.
    Frunza, M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Jimenez Lacave, A.
    NEUROENDOCRINOLOGY, 2011, 94 : 28 - 29
  • [36] Chemotherapy with gemcitabine as first-line treatment for advanced biliary tract carcinoma
    Giacobino, A.
    Satolli, M. A.
    Dongiovanni, D.
    Rahimi, F.
    Milanesi, E.
    Zanini, M.
    Scigliano, M. C.
    Monge, T.
    Ceccarelli, M.
    Novarino, A.
    Ciorba, A.
    Manazza, A.
    Bertetto, O.
    Ciuffreda, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 16 - 16
  • [37] Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
    Luo, Jia
    Gao, Benjian
    Lin, Zhiyu
    Fan, Hua
    Ma, Wen
    Yu, Danfei
    Yang, Qian
    Tian, Jing
    Yang, Xiaoli
    Li, Bo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Combined atezolizumab and bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A single center experience
    Khalil, A. A.
    Abdelaziz, M. A.
    El Nahas, T. I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1492 - S1493
  • [39] BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma
    James E. Frampton
    Gillian M. Keating
    BioDrugs, 2008, 22 : 113 - 120
  • [40] Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
    He, Ying
    Lin, Wangchun
    Cai, Zhongjie
    Huang, Yufan
    You, Maojin
    Lei, Meisheng
    Chen, Ruijia
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345